NCT07132515

Brief Summary

We will give an anticoagulant against portal vein thrombosis, and watch for the results.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Aug 2023

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 15, 2023

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2025

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

August 10, 2025

Completed
10 days until next milestone

First Posted

Study publicly available on registry

August 20, 2025

Completed
Last Updated

August 20, 2025

Status Verified

August 1, 2025

Enrollment Period

2 years

First QC Date

August 10, 2025

Last Update Submit

August 17, 2025

Conditions

CirrhosisHCC - Hepatocellular CarcinomaPortal Vein Thrombosis

Outcome Measures

Primary Outcomes (1)

  • Portal vein thrombosis

    determine if thrombus resolved or not on anticcoagulant by triphasic CT

    6 months

Study Arms (3)

Anticoagulant in cirrhosis with HCC

EXPERIMENTAL

HCC patient on anticogulant like Enoxaparin (clexan), warfarrin(marivan), or DOAC(apixaban)

Drug: Enoxaparin, warfarrin, or apixaban

Anticoagulant in Cirrhosis without HCC

EXPERIMENTAL

Benign thrombus in cirrhotic patient on anticoagulant like Enoxaparin (clexan), warfarrin(marivan), or DOAC(apixaban)

Drug: Enoxaparin, warfarrin, or apixaban

No anticoagualnt in Cirrhosis with or without HCC

NO INTERVENTION

cirrhotic patients with thrombosis with or without HCC not on anticoagulant

Interventions

Enoxaparin, warfarrin, or apixabanDRUG

Enoxaparin, warfarrin, or apixaban

Anticoagulant in Cirrhosis without HCCAnticoagulant in cirrhosis with HCC

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Portal vein thrombosis, Cirrhosis, With or without HCC, Child A \& B

You may not qualify if:

  • Platelets\<10000, Createnine \>1.9, Budd ciarri, Uncontrolled active bleeding

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mansoura University Hospitals

Al Mansurah, Dakahlia Governorate, 35511, Egypt

RECRUITING

MeSH Terms

Conditions

FibrosisCarcinoma, Hepatocellular

Interventions

Enoxaparinapixaban

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and SymptomsAdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsLiver NeoplasmsDigestive System NeoplasmsNeoplasms by SiteDigestive System DiseasesLiver Diseases

Intervention Hierarchy (Ancestors)

Heparin, Low-Molecular-WeightHeparinGlycosaminoglycansPolysaccharidesCarbohydrates

Central Study Contacts

Dalia Elsayed Ganady, MBBS

CONTACT

+201095529264dalia.tawfik97@gmail.com

Hatem Elalfy, PhD

CONTACT

+201224790518elalfy2004@mans.edu.eg

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NON RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 10, 2025

First Posted

August 20, 2025

Study Start

August 15, 2023

Primary Completion

August 1, 2025

Study Completion

August 1, 2025

Last Updated

August 20, 2025

Record last verified: 2025-08

Data Sharing

IPD Sharing
Will share

when this clinical trial will be finished and have the results

Locations

EG(1)